<DOC>
	<DOCNO>NCT02991209</DOCNO>
	<brief_summary>The overall purpose study evaluate effect 12 month testosterone replacement therapy testicular cancer survivor mild Leydig Cell Insufficiency order reduce risk cardiovascular disease . The primary study objective evaluate change insulin sensitivity . The secondary study objective evaluate change prevalence metabolic syndrome , body composition , systemic inflammation symptom testosterone deficiency .</brief_summary>
	<brief_title>Study Testosterone v Placebo Testicular Cancer Survivors</brief_title>
	<detailed_description>This single-center , randomize , double-blind , placebo-controlled intervention study , design evaluate effect testosterone replacement therapy testicular cancer survivor mild Leydig Cell Insufficiency . 70 subject randomize receive either testosterone replacement therapy placebo . The subject invite information meeting informed consent sign . If subject suitable participation trial , subject randomize testosterone replacement therapy placebo baseline investigation perform . Afterwards , 52-weeks treatment period begin subject receive daily dose testosterone placebo . Dose adjustment make three time first 8 week study . Evaluation primary secondary endpoint perform 26 week , end treatment ( 52 week ) three month completion treatment ( week 64 ) .</detailed_description>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Testicular Neoplasms</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Signed informed consent . Previous treatment testicular cancer . No sign relapse 1 year last treatment ( orchiectomy , radiotherapy , chemotherapy ) . Free testosterone &lt; ageadjusted median &gt; 2 standard deviation ( SD ) ageadjusted median LH &gt; 2 SD ageadjusted median . Treatment testosterone within last 6 month . Contraindications testosterone treatment ( prostate cancer , prostate specific antigen ( PSA ) &gt; 4 ng/mL ) , malignancy suspect prostate digital rectal examination , Alanine aminotransferase ( ALT ) &gt; 1.5 upper reference level , Erythrocyte Volume Fraction ( EVF ) &gt; 50 % . Breast cancer . Symptomatic obstructive sleep apnoea syndrome Heart failure &gt; NYHA II . Uncontrolled hypertension : ( Systolic blood pressure &gt; 160 mm Hg despite antihypertensive treatment , measure two separate occasion ) Inability understand information trial Participation clinical trial Allergy active substance additive Tostran placebo . Known diabetes mellitus , diabetes mellitus detect screening baseline test .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>